Blood Sugar News and Research

RSS

Blood sugar concentration, or glucose level, refers to the amount of glucose present in the blood of a human or animal. Normally, in mammals the blood glucose level is maintained at a reference range between about 3.6 and 5.8 mM (mmol/l). It is tightly regulated as a part of metabolic homeostasis.

Halloween health tips for parents of children with diabetes

Ghosts, ghouls and goblins are suiting up for the yearly pilgrimage through neighborhoods shouting "Trick or Treat!" and begging for sweet treats that are synonymous with Halloween.

12 Oct 2011

Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the initiation of its first clinical trial to evaluate the Safety and Efficacy of PAZ320 when added to oral agents or Insulin regimen in Patients with Type 2 Diabetes Mellitus.

12 Oct 2011

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

DARA BioSciences, Inc. today announced the Journal of Pain and Symptom Management, an internationally respected, peer-reviewed journal, has published results of a Phase II safety and efficacy study of KRN5500 for the treatment of neuropathic pain in patients with cancer.

11 Oct 2011

Rare and severe hypoglycemia could be genetic

The life-threatening condition depicts the fact that the body does not have enough energy to function. Scientists at the University of Cambridge say mutations in the AKT2 gene are to blame. Writing in the journal Science, they say there are already cancer drugs which target a similar process.

10 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

First combination drug to treat type 2 diabetes and high cholesterol receives FDA approval

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin.

7 Oct 2011

Scientists discover rare genetic alteration responsible for hypoglycaemia

Cambridge scientists have identified the cause of a rare, life-threatening form of hypoglycaemia. Their findings, which have the potential to lead to pharmaceutical treatments for the disorder, were published today, 07 October, in the journal Science.

7 Oct 2011

Tight blood sugar control fails to improve memory in diabetics

A new study has shown that those with type 2 diabetes do not show slowing of the decline in thinking skills with intense blood sugar control. In fact such intense therapy raises risk of death.

2 Oct 2011

GWAS uncovers new genes associated with type 1 diabetes

The largest-ever analysis of genetic data related to type 1 diabetes has uncovered new genes associated with the common metabolic disease, which affects 200 million people worldwide. The findings add to knowledge of gene networks involved in the origin of this complex disorder, in which patients depend on frequent insulin injections to control their blood sugar levels.

30 Sep 2011

AstraZeneca settles SEROQUEL XR patent infringement litigation

AstraZeneca today announced it has entered into a settlement agreement in its U.S. SEROQUEL XR patent infringement litigation against Handa Pharmaceuticals, LLC regarding Handa's proposed generic version of AstraZeneca's SEROQUEL XR extended-release tablets.

30 Sep 2011

Intensive blood glucose control therapy provides no added benefit against cognitive decline in older diabetics

Intensive control of blood sugar levels beyond standard targets provides no additional protection against cognitive decline in older people with diabetes than standard treatment, according to a national study coordinated by researchers at Wake Forest Baptist Medical Center.

29 Sep 2011

FOX06 protein contributes to liver overproduction of glucose in diabetes

Researchers at the John G. Rangos Sr. Research Center at Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine have identified a powerful molecular pathway that regulates the liver's management of insulin and new glucose production, which could lead to new therapies for diabetes.

29 Sep 2011

Asthmatic kids with type 1 diabetes have tougher time maintaining healthy sugar levels: Study

The reason why asthma might complicate pediatric diabetes care remains unclear, however, and is “something that needs to be explored more,” said Dr. Anita Swamy, a pediatric endocrinologist and medical director of the Chicago Children's Diabetes Center at La Rabida Children's Hospital in Chicago. She was not involved in the new study. The study appears in the October issue of Pediatrics.

27 Sep 2011

UNC CDTR aims to reduce diabetes-related health disparities

The University of North Carolina at Chapel Hill has received a $3 million, 5-year grant from the National Institute of Diabetes and Digestive and Kidney Diseases to establish the UNC Center for Diabetes Translation Research to Reduce Health Disparities.

27 Sep 2011

UCSF, QuantiaMD develop new DiabetesIQ mobile phone app

A new interactive mobile phone app called DiabetesIQ, released this week, challenges people to test their knowledge of diabetes and to compete with one another as they learn about the complexities of the disease, which affects more than 25 million Americans, including 4 million Californians.

27 Sep 2011

JDRF, iCo Therapeutics collaborate for iCo-007 Phase 2 trial in DME

iCo Therapeutics Inc. today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema.

26 Sep 2011

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.

26 Sep 2011

New initiative for effective two-way communication between patients and clinicians

The U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality (AHRQ) today launched an initiative with the Ad Council to encourage clinicians and patients to engage in effective two-way communication to ensure safer care and better health outcomes.

22 Sep 2011

GI Dynamics introduces EndoBarrier Gastrointestinal Liner in Austria

GI Dynamics, Inc. today announced the launch of the EndoBarrier Gastrointestinal Liner in Austria, the establishment of the first two Centers of Excellence and the treatment of patients at each new Center.

21 Sep 2011